CYPHER PTE. LTD.
UEN: 201723575K
CYPHER PTE. LTD.(201723575K) is a Singapore business with registered business address at 12 MARINA VIEW, 23-1, ASIA SQUARE TOWER 2, Singapore 18961. They specialise in the area of DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C. and INFORMATION TECHNOLOGY CONSULTANCY (EXCEPT CYBERSECURITY).
| Company Name | CYPHER PTE. LTD. |
| Unique Entity Number | 201723575K |
| Entity Type | Local Company |
| Entity Status | Live Company |
| Incorporate Day | 18 August 2017 |
| Address |
12 MARINA VIEW #23-1 ASIA SQUARE TOWER 2 Singapore 18961 |
| Products / Services |
DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C. INFORMATION TECHNOLOGY CONSULTANCY (EXCEPT CYBERSECURITY) |
| Number of Officers | 3 |
| Paid Up Capital | SGD 100000 |
Breaking! Business News
OMERS Infrastructure Agrees to Purchase 19.4% Stake in Azure PowerOMERS Infrastructure Agrees to Purchase 19.4% Stake in Azure PowerTransaction expands Canadian pensi...
Read More
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages 360 DigiTech, Inc. Investors with Losses Over $100K to Secure Counsel Before Important September 13 Deadline in Securities Class Action – QFINROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages 360 DigiTech, Inc. Investors with Losses Over ...
Read More
RISULTATI DEL SECONDO TRIMESTRE 2021RISULTATI DEL SECONDO TRIMESTRE 2021GlobeNewswireJuly 30, 2021The following is an extract from the ...
Read More
India’s United Breweries becomes part of the HEINEKEN groupIndia’s United Breweries becomes part of the HEINEKEN groupGlobeNewswireJuly 30, 2021HEINEKEN obta...
Read More
AKWEL: TURNOVER INCREASES 26% IN THE FIRST HALF OF 2021AKWEL: TURNOVER INCREASES 26% IN THE FIRST HALF OF 2021GlobeNewswireJuly 30, 2021 Thu...
Read More
Responsible babies lifestyle brand, Malabar Baby, has launched a new collection of wearable blankets...
Read More
Sydney sportswear company Champion System Australia has updated its offerings with Glide fabric. Cus...
Read More
Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell CarcinomaJunshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab...
Read More